A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

被引：0
|
作者：
Quach, Hang [1 ]
Parmar, Gurdeep [2 ]
Ocio, Enrique M. [3 ]
Prince, H. Miles [4 ,5 ]
Oriol, Albert [6 ,7 ]
Crowther, Helen [8 ]
Tsukada, Nobuhiro [9 ]
Bories, Pierre [10 ]
Madan, Sumit [11 ]
Nathwani, Nitya [12 ]
Sunami, Kazutaka [13 ]
Semiond, Dorothee [14 ]
Yu, Disa [14 ]
Cordero, Paul [15 ]
Mace, Sandrine [16 ]
Suzan, Florence [16 ]
Moreau, Philippe [17 ]
机构：
[1] Univ Melbourne, St Vincents Hosp, Clin Hematol Serv, Melbourne, Australia
[2] Illawarra Canc Care Ctr, Wollongong, Australia
[3] Univ Cantabria, Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain
[4] Epworth HealthCare, Mol Oncol & Canc Immunol, Melbourne, Australia
[5] Univ Melbourne, Melbourne, Australia
[6] Hosp Germans Trias i Pujol, Inst Catala Oncol, Barcelona, Spain
[7] Hosp Germans Trias i Pujol, Inst Josep Carreras, Barcelona, Spain
[8] Blacktown & Mt Druitt Hosp, Dept Paediat, Blacktown, NSW, Australia
[9] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan
[10] Inst Univ Canc Toulouse, Inst Claudius Regaud, Inst Claudius Regaud, Toulouse, France
[11] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[12] City Hope Natl Med Ctr, Dept Hematol, Duarte, CA USA
[13] Natl Hosp Org Okayama Med Ctr, Dept Hematol, Okayama, Japan
[14] Sanofi, Res & Dev, Cambridge, MA USA
[15] Sanofi, Res & Dev, Reading, England
[16] Sanofi, Res & Dev, Vitry Sur Seine, France
[17] Univ Hosp Nantes, Dept Hematol, Nantes, France
来源：
HAEMATOLOGICA | 2024年 / 109卷 / 12期
关键词：
OPEN-LABEL;
D O I：
10.3324/haematol.2023.284730
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4078 / 4082
页数：5
相关论文
共 50 条
  • [31] Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma
    Shibayama, Hirohiko
    Matsumoto, Morio
    Kosugi, Hiroshi
    Shibayama, Kazuhiro
    Yamazaki, Hiroshi
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (01) : 112 - 121
  • [32] Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
    Jakubowiak, Andrzej J.
    Jasielec, Jagoda K.
    Rosenbaum, Cara A.
    Cole, Craig E.
    Chari, Ajai
    Mikhael, Joseph
    Nam, Jennifer
    McIver, Amanda
    Severson, Erica
    Stephens, Leonor A.
    Tinari, Kathryn
    Rosebeck, Shaun
    Zimmerman, Todd M.
    Hycner, Tyler
    Turowski, Agata
    Karrison, Theodore
    Zonder, Jeffrey A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (04) : 549 - 560
  • [33] Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study
    Gonzalez-Calle, Veronica
    Rodriguez-Otero, Paula
    Sureda, Anna
    de Arriba, Felipe
    Reinoso, Marta
    Ribas, Paz
    Gonzalez-Rodriguez, Ana Pilar
    Gonzalez, Yolanda
    Oriol, Albert
    Martinez-Lopez, Joaquin
    Gonzalez, Marta Sonia
    Hernandez, Miguel T.
    Sirvent, Maialen
    Cedena, Teresa
    Puig, Noemi
    Paiva, Bruno
    Blade, Joan
    Lahuerta, Juan Jose
    San-Miguel, Jesus F.
    Mateos, Maria -Victoria
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 2219 - 2228
  • [34] Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study
    Gonzalez-Calle, Veronica
    Rodriguez-Otero, Paula
    Sureda, Anna
    de Arriba, Felipe
    Reinoso, Marta
    Ribas, Paz
    Gonzalez-Rodriguez, Ana Pilar
    Gonzalez, Yolanda
    Oriol, Albert
    Martinez-Lopez, Joaquin
    Gonzalez, Marta Sonia
    Hernandez, Miguel T.
    Sirvent, Maialen
    Cedena, Teresa
    Puig, Noemi
    Paiva, Bruno
    Blade, Joan
    Lahuerta, Juan Jose
    San-Miguel, Jesus F.
    Mateos, Maria-Victoria
    HAEMATOLOGICA, 2024, 109 (07) : 2219 - 2228
  • [35] Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014
    Bahlis, Nizar J.
    Samaras, Christy
    Reece, Donna
    Sebag, Michael
    Matous, Jeffrey
    Berdeja, Jesus G.
    Shustik, Jesse
    Schiller, Gary J.
    Ganguly, Siddhartha
    Song, Kevin
    Seet, Christopher S.
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Fonseca, Gustavo
    Liu, Hongjuan
    Gentili, Christian
    Singh, Pavit
    Siegel, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (12): : 852 - 862
  • [36] Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients
    Martino, E. A.
    Palmieri, S.
    Galli, M.
    Derudas, D.
    Mina, R.
    Della Pepa, R.
    Zambello, R.
    Vigna, E.
    Bruzzese, A.
    Mangiacavalli, S.
    Zamagni, E.
    Califano, C.
    Musso, M.
    Conticello, C.
    Cerchione, C.
    Mele, G.
    Di Renzo, N.
    Offidani, M.
    Tarantini, G.
    Casaluci, G. M.
    Rago, A.
    Ria, R.
    Uccello, G.
    Barila, G.
    Palumbo, G.
    Pettine, L.
    De Magistris, C.
    Vincelli, I. D.
    Brunori, M.
    Accardi, F.
    Amico, V.
    Amendola, A.
    Fontana, R.
    Bongarzoni, V.
    Rossini, B.
    Cotzia, E.
    Gozzetti, A.
    Rizzi, R.
    Sgherza, N.
    Curci, P.
    Mancuso, K.
    Reddiconto, G.
    Maroccia, A.
    Franceschini, L.
    Bertuglia, G.
    Nappi, D.
    Barbieri, E.
    Quaresima, M.
    Petrucci, M. T.
    Di Raimondo, F.
    ESMO OPEN, 2025, 10 (02)
  • [37] Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
    Dosne, Anne-Gaelle
    Li, Xia
    Luo, Man Melody
    Nnane, Ivo
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Sonneveld, Pieter
    Kampfenkel, Tobias
    Carson, Robin
    Amin, Himal
    Ruixo, Juan Perez
    Zhou, Honghui
    Sun, Yu-Nien
    Xu, Yan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (05) : 1640 - 1655
  • [38] Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
    Facon, Thierry
    Moreau, Philippe
    Martin, Thomas G.
    Spicka, Ivan
    Oriol, Albert
    Koh, Youngil
    Lim, Andrew
    Mikala, Gabor
    Rosinol, Laura
    Yagci, Munci
    Cavo, Michele
    Yong, Kwee
    Risse, Marie-Laure
    Asset, Gaelle
    Schwab, Sandrine
    Martinez, Gracia
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (05) : 1020 - 1029
  • [39] Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma
    Mateos, Maria-Victoria
    Granell, Miguel
    Oriol, Albert
    Martinez-Lopez, Joaquin
    Blade, Joan
    Hernandez, Miguel T.
    Martin, Jesus
    Gironella, Mercedes
    Lynch, Mark
    Bleickardt, Eric
    Paliwal, Prashni
    Singhal, Anil
    San-Miguel, Jesus
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (03) : 448 - 456
  • [40] Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis
    Kim, Kihyun
    Min, Chang-Ki
    Koh, Youngil
    Ishizawa, Kenichi
    Kim, Sung-Hyun
    Ito, Shigeki
    Tanaka, Junji
    Uchiyama, Michihiro
    Kawano, Yawara
    Kim, Jin Seok
    Moreau, Philippe
    Martin, Thomas
    Dong, Yvonne
    Risse, Marie-Laure
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (04) : 553 - 562
12345